Listen: JPM21: Déjà vu in Alzheimer’s research, debatable valuations in biotech, and OWS’s legacy

Is Alzheimer’s research stuck in a rut? Can genome editing live up to the hype? And how will we remember Operation Warp Speed?

We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We’re devoting this episode to the news coming out of the just-concluded J.P. Morgan Healthcare Conference, the drug industry’s largest annual meeting. First, we’ll dissect Eli Lilly’s surprising data on a new Alzheimer’s disease treatment and dig into its implications for the field. Then, we discuss whether there’s a bubble inflating in the genome editing world, debate who will run the FDA under a President Biden, and consider the legacy of Moncef Slaoui, the outgoing leader of Operation Warp Speed.

Read the rest…

Read Original Article: Listen: JPM21: Déjà vu in Alzheimer’s research, debatable valuations in biotech, and OWS’s legacy »